Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents

Cochrane Database of Systematic Reviews

Volumn 2012, Issue 7, 2012, Pages

  Gillies, Donna ^a   Sinn, John K H ^b   Lad, Sagar S ^c   Leach, Matthew J ^d   Ross, Melissa J ^e  

^a WESTERN SYDNEY LOCAL HEALTH DISTRICT   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Jehangir Apollo Hospital   (India)

^d UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^e WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; DEXAMPHETAMINE; METHYLPHENIDATE; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID;

ARTICLE; ATTENTION DEFICIT DISORDER; COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL (TOPIC); DIET SUPPLEMENTATION; DRUG EFFICACY; HUMAN; HYPERACTIVITY; IMPULSIVENESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SIDE EFFECT; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 84877328222     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007986.pub2     Document Type: Article

References (97)

1. Aman MG, Mitchell EA, Turbott SH. The effects of essential fatty acid supplementation by Efamol in hyperactive children. Journal of Abnormal Child Psychology 1987;15(1):75-90.
2. Arnold LE, Kleykamp D, Votolato N, Gibson RA,Horrocks L. Potential link between dietary intake of fatty acids and behavior: pilot exploration of serum lipids in attentiondeficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology 1994;4(3):171-82.
3. Arnold LE, Kleykamp D, Votolato NA, Taylor WA, Kontras SB, Tobin K. Gamma-linolenic acid for attention-deficit hyperactivity disorder: placebo-controlled comparison to D-amphetamine. Biological Psychiatry 1989; 25(2):222-8.
4. Arnold LE, Pinkham SM, Votolato N. Does zinc moderate essential fatty acid and amphetamine treatment of attentiondeficit/ hyperactivity disorder?. Journal of Child and Adolescent Psychopharmacology 2000;10(2):111-7.
5. Belanger SA, Vanasse M, Spahis S, Sylvestre MP, Lippe S, L'Heureux F, et al.Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: a randomized, double-blind, placebo-controlled study. Paediatrics and Child Health 2009;14(2):89-98.
6. Brue AW, Oakland TD, Evans RA. The use of a dietary supplement combination and an essential fatty acid as an alternative and complementary treatment for children with attention-deficit/hyperactivity disorder. The Sciientific Review of Alternative Medicine 2001;5(4):187-94.
7. Gustafsson PA, Birberg-Thornberg U, Duchén K, Landgren M, Malmberg K, Pelling H, et al.EPA supplementation improves teacher-rated behaviour and oppositional symptoms in children with ADHD. Acta Pædiatrica 2010;99(10):1540-9.
8. Hamazaki T, Hirayama S. The effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - a placebocontrolled double-blind study. European Journal of Clinical Nutrition 2004;58(5):838.
9. Hirayama S, Hamazaki T, Terasawa K. Effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder -a placebo-controlled double-blind study. European Journal of Clinical Nutrition 2004;58(3):467-73.
10. Johnson M, Ostlund S, Fransson G, Kadesjo B, Gillberg C. Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder: a randomized placebo-controlled trial in children and adolescents. Journal of Attention Disorders 2009;12(5):394-401.
11. Manor I, Magen A, Keidar D, Rosen S, Tasker H, Cohen T, et al.The effect of phosphatidylserine containing omega3 fatty-acids on attention-deficit hyperactivity disorder symptoms in children: a double-blind placebo-controlled trial, followed by an open-label extension. European Psychiatry 2011:In Press.
12. Raz R, Carasso RL, Yehuda S. The influence of shortchain essential fatty acids on children with attention-deficit/ hyperactivity disorder: a double-blind placebo-controlled study. Journal of Child and Adolescent Psychopharmacology 2009;19(2):167-77.
13. Sinn N. Polyunsaturated fatty acid supplementation for ADHD symptoms: response to commentary. Journal of Developmental and Behavioral Pediatrics 2007;28(3):262-3.
14. Sinn N, Bryan J. Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. Journal of Developmental and Behavioral Pediatrics 2007;28 (2):82-91.
15. Sinn N, Bryan J, Wilson C. Cognitive effects of polyunsaturated fatty acids in children with attention deficit hyperactivity disorder symptoms: a randomised controlled trial. Prostaglandins Leukotrienes and Essential Fatty Acids 2008;78(4-5):311-26.
16. Stevens L, Zhang W, Peck L, Kuczek T, Grevstad N, Mahon A, et al.EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids 2003;38(10):1007-21.
17. Vaisman N, Kaysar N, Zaruk-Adasha Y, Pelled D, Brichon G, Zwingelstein G, et al.Correlation between changes in blood fatty acid composition and visual sustained attention performance in children with inattention: effect of dietary n-3 fatty acids containing phospholipids. American Journal of Clinical Nutrition 2008;87(5):1170-80.
18. Voigt RG, Llorente AM, Jensen CL, Fraley JK, Berretta MC, Heird WC. A randomized, double-blind, placebocontrolled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. Journal of Pediatrics 2001;139(2):189-96.
19. Anon. Omega-3/omega-6 fatty acids and ADHD. Brown University Child & Adolescent Psychopharmacology Update 2009;11(4):4-5.
20. Doebel JK, Keller G, Zierau M-T. Dietary therapy for children with ADHD. Deutsche Apotheker Zeitung 2005; 145(24):54-7.
21. Harding KL, Judah RD, Gant C. Outcome-based comparison of Ritalin versus food-supplement treated children with AD/HD. Alternative Medicine Review 2003;8 (3):319-30.
22. Joshi K, Lad S, Kale M, Patwardhan B, Mahadik SP, Patni B, et al.Supplementation with flax oil and vitamin C improves the outcome of attention deficit hyperactivity disorder (ADHD). Prostaglandins Leukotrienes and Essential Fatty Acids 2006;74(1):17-21.
23. Richardson AJ, Puri BK. A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2002;26(2):233-9.
24. Bos D, Van Belle J, Weusten J, Hoeksma M, Wiseman S, Durston S. Effects of N-3 fatty acids (DHA and EPA) on cognitive control and associated brain activity in ADHD: a double-blind placebo controlled study. European Child and Adolescent Psychiatry 2010; Vol. 19, issue Suppl 1:S69.
25. Omega-3 supplementation and attention-deficithyperactivity disorder (ADHD). Ongoing study April 2009.
26. PAD-Study - Efficacy of polyunsaturated fatty acids in children and adolescents with attention deficit/hyperactivity disorder (ADHD). Ongoing study Recruiting 1 August 2011.
27. Clinical trial to evaluate the efficacy and the tolerance of an omega 3 fatty acids supplementation in ADHD children. Ongoing study October 2008.
28. Randomised controlled trial investigating effect of supplementation with omega-3 fatty acids EPA and DHA versus omega-6 fatty acid LA on ADHD symptoms and learning difficulties in 7-12 year old children. Ongoing study 16 July 2007.
29. Omega-3 fatty acids supplementation for adolescent boys with attention deficit hyperactivity disorder: a doubleblind, randomized controlled trial. Ongoing study 20 March 2006.
30. Omega-3 fatty acids as an adjunctive therapy for treatment in attention-deficit hyperactivity disorder (ADHD). Ongoing study June 2009.
31. Effect of long chain polyunsaturated fatty acids on behavior and cognition in children with attention deficit hyperactivity disorder. Ongoing study April 2009.
32. Achenbach TM, Edelbrock CS. Manual for the Child Behavior Checklist. Burlington, VT: University of Vermont, Department of Psychiatry, 1983.
33. Agostoni C. Role of long-chain polyunsaturated fatty acids in the first year of life. Journal of Pediatric Gastroenterology and Nutrition 2008;47 (Suppl 2):S41-4.
34. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313(7066):1200.
35. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington DC: American Psychiatric Association, 1994.
36. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (text revision). Washington, DC: American Psychiatric Association, 2000.
37. Assisi A, Banzi R, Buonocore C, Capasso F, Di Muzio V, Michelacci F, et al.Fish oil and mental health: the role of n-3 long-chain polyunsaturated fatty acids in cognitive development and neurological disorders. International Clinical Psychopharmacology 2006;21(6):319-36.
38. Banaschewski T, Roessner V, Dittmann RW, Santosh PJ, Rothenberger A. Non-stimulant medications in the treatment of ADHD. European Child & Adolescent Psychiatry 2004;13(Suppl 1):102-16.
39. Barkley RA. Diagnosis and assessment of attention deficithyperactivity disorder. Comprehensive Mental Health Care 1991;1(1):27-43.
40. Barkley R. Attention-deficit Hyperactivity Disorders: a Handbook for Diagnosis and Treatment. 2nd Edition. New York: Guilford Press, 1998.
41. Biederman J. Attention-deficit/hyperactivity disorder: a selective overview. Biological Psychiatry 2005;57(11): 1215-20.
42. Bloch MH, Qawasmi A. Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and meta-analysis. Journal of the American Academy of Child and Adolescent Psychiatry 2011;50(10): 991-1000.
43. Borsonelo EC, Galduroz JCF. The role of polyunsaturated fatty acids (PUFAs) in development, aging and substance abuse disorders: review and propositions. Prostaglandins Leukotrienes and Essential Fatty Acids 2008;78(4-5):237-45.
44. Burgess JR, Stevens L, Zhang W, Peck L. Long-chain polyunsaturated fatty acids in children with attentiondeficit hyperactivity disorder. American Journal of Clinical Nutrition 2000;71(Suppl 1):327-30.
45. Cantwell DP. Attention deficit disorder: a review of the past 10 years. Journal of the American Academy of Child Adolescent Psychiatry 1996;35(8):978-87.
46. Chen J-R, Hsu S-F, Hsu C-D, Hwang L-H, Yang S-C. Dietary patterns and blood fatty acid composition in children with attention-deficit hyperactivity disorder in Taiwan. Journal of Nutritional Biochemistry 2004;15(8):467-72.
47. Conners CK, Sitarenios G, Parker JDA, Epstein JN. Revision and restandardization of the Conners Teacher Rating Scale (CTRS-R): factor structure, reliability, and criterion validity. Journal of Abnormal Child Psychology 1998;26(4):279-91.
48. Daley KC. Update on attention-deficit/hyperactivity disorder. Current Opinion in Pediatrics 2004;16(2):217-26.
49. Faraone SV. Genetics of childhood disorders: XX ADHD Part 4: is ADHD genetically heterogeneous?. Journal of the American Academy of Child Adolescent Psychiatry 2000;39 (11):1455-7.
50. Faraone SV, Wilens T. Does stimulant treatment lead to substance use disorders?. Journal of Clinical Psychiatry 2003; 64(Suppl 11):9-13.
51. Findling RL, Dogin JW. Psychopharmacology of ADHD in children and adolescents. Journal of Clinical Psychiatry 1998;59(7):42-9.
52. Froehlich TE, Anixt JS, Loe IM, Chirdkiatgumchai V, Kuan L, Gilman RC. Update on environmental risk factors for attention-deficit/hyperactivity disorder. Current Psychiatry Reports 2011;13(5):333-44.
53. Furman L. What is attention-deficit hyperactivity disorder (ADHD)?. Journal of Child Neurology 2005;20(12):994-1002.
54. Gill M, Daly G, Heron S, Hawi Z, Fitzgerald M. Confirmation of association between attention deficit hyperactivity disorder and a dopamine transporter polymorphism. Molecular Psychiatry 1997;2(4):311-3.
55. Golder S, Loke YK. Is there evidence for biased reporting of published adverse effects data in pharmaceutical industryfunded studies?. British Journal of Clinical Pharmacology 2008;66(6):767-73.
56. Goodman R, Stevenson J. A twin study of hyperactivity II: the aetiological role of genes, family relationships and perinatal adversity. Journal of Child Psychology and Psychiatry 1989;30(5):691-709.
57. Haag M. Essential fatty acids and the brain. Canadian Journal of Psychiatry 2003;48(3):3195-203.
58. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Archives of General Psychiatry 2006;63(3):332-9.
59. Harpin VA. The effect of ADHD on the life of an individual their family and community from preschool to adult life. Archives of Disease in Childhood 2005;90(Suppl 1):12-7.
60. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
61. Innis SM. The role of dietary n-6 and n-3 fatty acids in the developing brain. Developmental Neuroscience 2000;22(5-6):474-80.
62. Klassen A, Miller A, Raina P, Lee SK, Olsen L. Attentiondeficit hyperactivity disorder in children and youth: a quantitative systematic review of the efficacy of different management strategies. Canadian Journal of Psychiatry 1999;44(10):1007-16.
63. Kovacs M. Children's Depression Inventory. https://www.mhs.com/ecom/(3jkh5055rnqsekfhnxgzn145)/TechBrochures/CDI.pdf (accessed 18 May 2007).
64. Krause KH, Dresel SH, Krause J, la Fougere C, Ackenheil M. The dopamine transporter and neuroimaging in attention deficit hyperactivity disorder. Neuroscience Biobehavioral Reviews 2003;27(7):605-13.
65. Langley K, Rice F, van den Bree MBM, Thapar A. Maternal smoking during pregnancy as an environmental risk factor for attention deficit hyperactivity disorder behaviour. A review. Minerva Pediatrica 2005;57(6):359-71.
66. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003;326(7400):1167-70.
67. Li D, Sham PC, Owen MJ, He L. Meta-analysis shows significant association between dopamine system genes and attention deficit hyperactivity disorder (ADHD). Human Molecular Genetics 2006;15(14):2276-84.
68. Linnet KM, Dalsgaard S, Obel C, Wisborg K, Henriksen TB, Rodriguez A, et al.Maternal lifestyle factors in pregnancy risk of attention deficit hyperactivity disorder and associated behaviors: review of the current evidence. American Journal of Psychiatry 2003;160(6):1028-40.
69. Mitchell EA, Aman MG, Turbott SH, Manku M. Clinical characteristics and serum essential fatty acid levels in hyperactive children. Clinical Pediatrics 1987;26(8):406-11.
70. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al.Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? . Lancet 1998;352(9128):609-13.
71. Morrell J, Murray L. Parenting and the development of conduct disorder and hyperactive symptoms in childhood: a prospective longitudinal study from 2 months to 8 years. Journal of Child Psychology and Psychiatry 2003;44(4): 489-508.
72. National Institutes of Health Consensus Development Conference Statement: diagnosis and treatment of attention-deficit/hyperactivity disorder (ADHD). Journal of the American Academy of Child & Adolescent Psychiatry 2000; Vol. 39, issue 2:182-93.
73. Pelham WE, Foster EM, Robb JA. The economic impact of attention-deficit/hyperactivity disorder in children and adolescents. Journal of Pediatric Psychology 2007;32(6):711-27.
74. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. American Journal of Psychiatry 2007;164(6):942-8.
75. Raskin LA, Shaywitz SE, Shaywitz BA, Anderson GM, Cohen DJ. Neurochemical correlates of attention deficit disorder. Pediatric Clinics of North America 1981;31(2): 387-96.
76. Raz R, Gabis L. Essential fatty acids and attention-deficithyperactivity disorder: a systematic review. Developmental Medicine and Child Neurology 2009;51(8):580-92.
77. Richardson AJ, Puri BK. The potential role of fatty acids in attention-deficit/hyperactivity disorder. Prostaglandin, Leukotrienes and Essential Fatty Acids 2000;63(1-2):79-87.
78. Richardson AJ. Clinical trials of fatty acid treatment in ADHD, dyslexia, dyspraxia and the autistic spectrum. Prostaglandins Leukotrienes and Essential Fatty Acids 2004;70 (4):383-90.
79. Richardson AJ. Omega-3 fatty acids in ADHD and related neurodevelopmental disorders. International Review of Psychiatry 2006;18(2):155-72.
80. Schab DW, Trinh NH. Do artificial food colors promote hyperactivity in children with hyperactive syndromes? Ameta-analysis of double-blind placebo-controlled trials. Journal of Developmental Behavioral Pediatrics 2004;25(6):423-34.
81. Schachter H, Kourad K, Merali Z, Lumb A, Tran K, Miguelez M, et al.Effects of Omega-3 Fatty Acids on Mental Health. Evidence Report/Technology Assessment No 116 (Publication No 05-E022-2). Rockville, MD: Agency for Healthcare Research and Quality, July 2005.
82. Shaywitz B, Fletcher J, Shaywitz S. Attention-deficit/hyperactivity disorder. Advances in Pediatrics 1997;44:331-67.
83. Simeon JG, Wiggins DM. Pharmacotherapy of attention deficit hyperactivity disorder. Canadian Journal of Psychiatry 1993;38(6):443-8.
84. Simmer K, Schulzke SM, Patole S. Longchain polyunsaturated fatty acid supplementation in preterm infants. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD000375.pub4]
85. Simmer K, Patole S, Rao S. Longchain polyunsaturated fatty acid supplementation in infants born at term. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI:10.1002/14651858.CD000376.pub2]
86. Simopoulos AP. Omega-3 fatty acids in health and disease and in growth and development. American Journal of Clinical Nutrition 1991;54(3):438-63.
87. Sinn N, Milte C, Howe PRC. Oiling the brain: a review of randomized controlled trials of omega-3 fatty acids in psychopathology across the lifespan. Nutrients 2010;2(2): 128-70.
88. Spielberger CD. Manual for the State-Trait Anxiety Inventory for Children. Palo Alto, CA: Consulting Psychologists Press, 1973.
89. Stevens LJ, Zentall SS, Deck JL, Abate ML, Watkins BA, Lipp SR, et al.Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder. American Journal of Clinical Nutrition 1995;62(4):761-8.
90. Swanson JM, McBumett K, Wigal T. Effect of stimulant medication on children with attention deficit disorder: a "review of reviews". Exceptional Children 1993;60(2):154-62.
91. Swanson J, Oosterlaan J, Murias M, Schuck S, Flodman P, Spence MA, et al.Attention deficit/hyperactivity disorder children with a 7-repeat allele of the dopamine receptor D4 gene have extreme behaviour but normal performance on critical neuropsychology tests of attention. Proceedings of the National Academy of Sciences 2000;97(9):4754-9.
92. Swanson JM, KinsbourneM, Nigg J, Lanphear B, Stefanatos GA, Volkow N, et al.Etiologic subtypes of attention-deficit/ yperactivity disorder: brain imaging, molecular genetic and environmental factors and the dopamine hypothesis. Neuropsychology Review 2007;17(1):39-59.
93. Varni JW, SeidM, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory™version 4.0 generic core scales in healthy and patient populations. Medical Care 2001;39(8):800-12.
94. Wainwright PE. Do essential fatty acids play a role in brain and behavioral development?. Neuroscience and Biobehavioral Reviews 1992;16(2):193-205.
95. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders. http://apps.who.int/classifications/icd10/browse/2010/en. Geneva: WHO,2010.
96. Wilens TE. Attention-deficit/hyperactivity disorder and the substance use disorders: the nature of the relationship who is at risk and treatment issues. Primary Psychiatry 2004;11 (7):63-70.
97. Zappitelli M, Pinto T, Grizenko N. Pre- peri- and postnatal trauma in subjects with attention-deficit hyperactivity disorder. Canadian Journal of Psychiatry 2001;46(6):542-8.